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The p53 tumor suppressor protein is a transcription factor that plays a
prominent role in protecting cells from malignant transformation. Protein
levels of p53 and its transcriptional activity are tightly regulated by the
ubiquitin E3 ligase MDM2, the gene expression of which is transcription-
ally regulated by p53 in a negative feedback loop. The p53 protein is tran-
scriptionally active as a tetramer, and this oligomerization state is
modulated by a complex formed by NEURL4 and the ubiquitin E3 ligase
HERC2. Here, we report that MDM2 forms a complex with oligomeric
p53, HERC2, and NEURL4. HERC2 knockdown results in a decline in
MDM2 protein levels without affecting its protein stability, as it reduces its
mRNA expression by inhibition of its promoter activation. DNA damage
induced by bleomycin dissociates MDM2 from the p53/HERC2/NEURL4
complex and increases the phosphorylation and acetylation of oligomeric
p53 bound to HERC2 and NEURL4. Moreover, the MDM2 promoter,
which contains p53-response elements, competes with HERC2 for binding
of oligomeric, phosphorylated and acetylated p53. We integrate these find-
ings in a model showing the pivotal role of HERC2 in p53-MDM2 loop
regulation. Altogether, these new insights in p53 pathway regulation are of
great interest in cancer and may provide new therapeutic targets.
1. Introduction
The TP53 gene encodes the p53 tumor suppressor pro-
tein which is a master transcription regulator of an exten-
sive number of genes involved in apoptosis, proliferation,
senescence, and metabolism among other cellular pro-
cesses. In response to a wide range of cellular stresses
including DNA damage, p53 activates this complex
antiproliferative transcriptional program. TP53 is the
most frequently mutated gene in human cancer. Inacti-
vating mutations of this gene are common, being linked
to poor patient prognosis. Consistent with a tumor sup-
pressor function, the TP53 gene is mutated in more than
half of all sporadic cancers and patients with Li-Frau-
meni syndrome (who are cancer prone) harbor germline
TP53mutations (Kastenhuber and Lowe, 2017).
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In nonstressed cells, p53 protein levels are low due
to its proteasomal degradation after polyubiquitylation
mediated mainly by the ubiquitin E3 ligase MDM2
(Haupt et al., 1997; Kubbutat et al., 1997; Michael
and Oren, 2003). MDM2 also controls its own degra-
dation through a self-catalytic mechanism (Fang et al.,
2000; Honda and Yasuda, 2000). In stressed cells,
MDM2 proteasomal degradation is stimulated and
p53 becomes more stable and is activated (Horn and
Vousden, 2007). During this activation process, p53
oligomerizes and is phosphorylated by kinases at sev-
eral threonine/serine residues and acetylated by acetyl-
transferases at multiple lysine residues (Cubillos-Rojas
et al., 2014; Itahana et al., 2009; Tang et al., 2008).
Activated p53 binds to p53 response elements located
in the promoter of its target genes to activate or
repress their transcription (Fischer et al., 2015).
MDM2 is one of these p53 target genes. Hence, this
forms a negative feedback loop (Karni-Schmidt et al.,
2016; Manfredi, 2010).
The p53 protein contains a functional domain at the
C terminus of its structure that permits its oligomeriza-
tion. It is believed that in nonstressed cells, p53 exists
predominantly in a dimer state. Upon a stress signal,
p53 concentration increases, shifting to a tetramer state
that binds with more affinity to DNA and regulating
the transcription of its target genes (Kawaguchi et al.,
2006; Stommel et al., 1999; Weinberg et al., 2004). The
oligomerization state also affects other aspects of p53
function such as its post-translational modifications, its
degradation, and its interaction with other proteins
(Chene, 2001; Kamada et al., 2016). Since acetylation is
indispensable for p53 activation (Tang et al., 2008) and
p53 oligomerization is essential for its acetylation (Ita-
hana et al., 2009), p53 oligomerization is a critical step
during its transcriptional activation. Most mutations in
the oligomerization domain of p53 prevent its
oligomerization, its binding to DNA, its transcriptional
activity and are associated with tumor progression as
occurs in patients with Li-Fraumeni and Li-Fraumeni-
like syndromes (Davison et al., 1998; Lomax et al.,
1998). The ubiquitin E3 ligase HERC2 and the
NEURL4 protein are required for oligomerization and
subsequent transcriptional activation of p53 (Cubillos-
Rojas et al., 2014, 2017).
HERC2 belongs to the large HERC family of ubiq-
uitin E3 ligases. Members of this family contain more
than one regulator of chromosome condensation 1
(RCC1)-like domain (RLD) and a homologous to the
E6AP carboxyl terminus (HECT) ubiquitin ligase
domain (Garcıa-Cano et al., 2019; Sanchez-Tena et al.,
2016). HERC2 is the only member of this small family
that contains a p53-binding domain named CPH due
to its presence in cullin 7 (CUL7), Parkin-like cyto-
plasmic (PARC), and HERC2 itself. Proteins with a
CPH domain bind p53 and regulate its activity in dif-
ferent ways. Thus, whereas CUL7 and PARC promote
cell growth by antagonizing p53 functions, HERC2
activates p53, thus inhibiting cell cycle progression
(Andrews et al., 2006; Cubillos-Rojas et al., 2014; Kas-
per et al., 2006; Kaustov et al., 2007; Nikolaev et al.,
2003). Substrates of HERC2, such as XPA, BRCA1,
USP33, and FBXL5, relate this E3 ligase to cellular
processes such as DNA repair, centrosome structure,
and iron metabolism (Garcıa-Cano et al., 2019;
Sanchez-Tena et al., 2016). Genetic studies have asso-
ciated the HERC2 locus with human pigmentation,
neuronal disorders, and cancer (for review, see Refs
Garcıa-Cano et al., 2019; Sanchez-Tena et al., 2016).
For example, a neurodevelopmental delay featuring
Angelman syndrome and autism spectrum disorder has
been attributed to a homozygous missense mutation
[NM_004667.5:c.1781C>T (p.Pro594Leu)] in the
HERC2 gene (Harlalka et al., 2013; Puffenberger
et al., 2012) or to a homozygous 286-kb deletion
between the contiguous genes HERC2 and OCA2
(chr15: g. 28143765_28429460 del) (Morice-Picard
et al., 2016). Mutations in HERC2 have also been
described in leukemia (Johansson et al., 2018), and
gastric and colorectal carcinomas [NM_004667.5:
c.541delA (p.Ser181ValfsX85)] (Yoo et al., 2011).
The molecular mechanism involved in the regulation
of the transcriptional activity of p53 is complex.
Although numerous studies have contributed to an
emerging model of regulation, it is necessary to under-
stand how newly identified interactors integrate with
this model. The formation of a complex between
HERC2 and p53 led us to investigate whether HERC2
participates in the negative feedback loop of p53 and
MDM2, whereby p53 activates the transcription of
MDM2, and MDM2 inhibits the transcriptional activ-
ity of p53, facilitates its cytoplasmic localization, and
promotes its degradation. In the current study, we iden-
tified an interaction between HERC2, p53, and MDM2
in which p53 oligomerization is essential for the forma-
tion of this complex. HERC2 regulates MDM2 gene
expression by a p53-dependent transcriptional mecha-
nism. Moreover, the HERC2-p53-MDM2 interaction is
regulated by DNA damage. Following DNA damage
caused by bleomycin, oligomeric p53 is phosphorylated
and acetylated, and MDM2 is dissociated from the
complex. Our findings also show that the MDM2 pro-
moter containing p53 response elements, binds acety-
lated, phosphorylated, and oligomeric p53, displacing it
from the complex with HERC2. These data have signif-
icant implications in the model of regulation of p53
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activity, revealing that HERC2 is a critical component
in regulation of the p53-MDM2 loop.
2. Methods
2.1. Cell lines, culture conditions, and treatments
U2OS, HEK293T, A549, and H1299 cell lines were
obtained from ATCC (Manassas, VA, USA) and cultured
in Dulbecco’s modified Eagle’s medium (01-055-1A) sup-
plemented with 10% fetal bovine serum (04-007-1A),
100 UmL1 penicillin, and 0.1 mgmL1 streptomycin
sulfate (03-031-1B) and 2 mM L-glutamine (03-020-1B)
from Biological Industries (Beit HaEmek, Israel). Cells
were treated where indicated with 20 lgmL1 cyclohex-
imide (C7698), 10 lgmL1 (0.015 UmL1) bleomycin
sulfate (B5507) or 10 lM MG132 (C2211) from Sigma-
Aldrich/Merck (Darmstadt, Germany).
2.2. Plasmids and siRNAs transfection
pcDNA3-Flag-MDM2 plasmid, p53 constructs (wt,
R337C, L344P, NLS, NES, and p53-CFP) and Myc-
tagged F3 fragment from HERC2 (residues 2292–
2923) containing the CPH domain were obtained from
Burgering (Brenkman et al., 2008), Zhang (Itahana
et al., 2009), and Ohta (Wu et al., 2010), respectively.
For gene interference, custom double-stranded siRNA
oligonucleotides were obtained from GeneCust (Boy-
nes, France) and previously tested among others else-
where (Cubillos-Rojas et al., 2014). Forward sequences
were nontargeting (NT): 50-UAGCGACUAAACAC
AUCAAdTdT-30, HERC2: 50-ACUGUAGCCAGAU
UGAAAdTdT-30, and MDM2: 50-GAAGUUAUUA
AAGUCUGUUdTdT-30, along with their respective
reverse oligonucleotides. Interference with siRNAs was
carried out by transfecting the oligonucleotides using
the calcium phosphate method as described elsewhere
(Cubillos-Rojas et al., 2014). Plasmid transfection was
performed using the Lipofectamine LTX method
(15338; Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions.
2.3. Protein extraction, PAGE, western blot, and
antibodies
For protein extraction, cells were washed twice in ice-
cold PBS after media were discarded and lysed by scrap-
ing with 100 lL lysis buffer every one million cells (lysis
buffer was composed by 0.3% CHAPS with 100 mM
NaCl in 10 mM Tris/HCl, pH = 7.5; supplemented with
protease and phosphatase inhibitors: 50 mM NaF,
50 mM b-glycerophosphate, 1 mM PMSF, 1 mgmL1
benzamidine, 5 lgmL1 leupeptin, 1 lgmL1 pep-
statin A, 5 lgmL1 aprotinin, 1 lM E64, and 1 mM
Na3VO4). Lysates were centrifuged at 13 000 g for
10 min at 4 °C, and pellets were discarded. Protein con-
centrations were quantified using a BCA kit (23223 and
23224) supplied by Thermo Scientific (Waltham, MA,
USA) according to the manufacturer’s instructions.
Gradient (3–15%) polyacrylamide gel electrophoresis
and protein transfer were performed as previously
described (Cubillos-Rojas et al., 2010). Band intensity
was measured, when indicated, using IMAGEJ software
(Collins, 2007; Schneider et al., 2012).
Antibodies were from the following companies: BD
Transduction (HERC2, 612366, Franklin Lakes, NJ,
USA), Abcam (MDM2 2A10, ab16895, Cambridge,
UK), Santa Cruz Biotechnology (Dallas, TX, USA)
[p53 DO-1 (mouse), sc-126; p53 N-19 (goat, used in
western blots for immunoprecipitation assays), sc-
1314; a-tubulin, sc-53646; p21, sc-397 and NEURL4,
sc-243602], Sigma-Aldrich/Merck (Flag M2, F1804),
Roche (c-Myc, 11667149001, Basel, Switzerland), and
Cell Signaling Technology (P-p53 S15, #9284 and Ac-
p53 K382, #2525, Danvers, MA, USA).
2.4. Immunoprecipitation, oligo pulldown, and
oligomerization assays
For immunoprecipitation, 1 mg protein from cell lysates
was incubated at 4 °C for 2 h on a rotatory wheel with
polyclonal HERC2 antibody bvg3 (generated against
residues 1–199 as described elsewhere, Cubillos-Rojas
et al., 2014), Myc antibody (11667149001) from Roche,
or anti-Flag M2 Affinity Gel (A2220) from Sigma/Mer-
ck. For the HERC2 and Myc immunoprecipitations,
protein A-conjugated sepharose slurry (71-7090-00) from
GE Healthcare (Chicago, IL, USA) was washed twice in
wash buffer (lysis buffer described in Section 2.3, without
inhibitors) and added to the lysates, which were left for
incubation in the same conditions for one additional
hour. After this time, lysates were centrifuged at 2500 g
for 2 min at 4 °C and washed four times in 1 mL wash
buffer. Pellets were resuspended in 29 loading buffer
[0.5 M Tris/HCl, pH = 8.5; 40 mgmL1 LDS,
0.3 mgmL1 EDTA, 20% glycerol, 0.0375% Coomassie
blue, 0.0125% phenol red, and 100 mM dithiothreitol
(DTT)] and stored at 20 °C until they were analyzed.
Inputs represent 1/25 from total cell lysates.
Protein lysates for oligo pulldown were harvested by
scraping in oligo pulldown lysis buffer [100 mM KCl,
10 mM HEPES pH = 7.9, 10% glycerol, 1 mM DTT,
5 mM MgCl2, 0.1% Nonidet P-40 (NP-40) substitute
(786–511) from GBiosciences (St. Louis, MO, USA),
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supplemented with the protease and phosphatase inhibi-
tors mentioned in Section 2.3] and centrifuged at
13 000 g for 10 min at 4 °C. Pellets were discarded and
supernatants were incubated overnight at 4 °C on a rota-
tory wheel with 1 lg double-stranded 50-biotinylated
oligonucleotides along with 1 lg poly-dIdC (sc-286691A)
from Santa Cruz Biotechnology. The oligonucleotide for-
ward sequences were as follows: Sp1 (murine Col1a1
promoter, as negative control): 50-BIOGGAACAGA
AGGGGAGGAGC-30; p21: 50-BIOGTCAGGAA-
CATGTCCCAACATGTTGAGCTC-30; MDM2wt: 50-
BIOGAGCTGGTCAAGTTCAGACACGTTCCGAA-
A-30 and MDM2mut: 50-BIOGAGCTGGTTAAAT
TCAGATACATTCCGAAA-30, along with their respec-
tive unmodified reverse oligonucleotides. Streptavidin-
conjugated agarose slurry (17-5113-01) from GE Health-
care was washed twice in wash buffer (oligo pulldown
lysis buffer with no NP-40 substitute or inhibitors) and
added to the lysates, which were left for incubation in the
same conditions for one additional hour. After that,
lysates were centrifuged at 1250 g and 4 °C for 1 min
and washed four times in the same wash buffer. Pellets
were resuspended in 29 loading buffer and stored at
20 °C until they were analyzed. Inputs represent 1/25
from total cell lysates.
For the oligomerization assays, glutaraldehyde solu-
tion was added to the pulldown products to a final
concentration of 0.04% in wash buffer and incubated
for 30 min on ice with mild rocking before loading
buffer was added (Cubillos-Rojas et al., 2014).
2.5. Quantitative real-time PCR
Total RNA isolation, reverse transcription, and quan-
tification were performed as previously described
(Cubillos-Rojas et al., 2017). Taqman assay probes for
MDM2 (Hs00540450_s1) and GAPDH
(Hs99999905_m1) were obtained from Thermo Scien-
tific.
2.6. Luciferase assays
U2OS and H1299 cells were transfected with either
pGL2-hmdm-Hx (wt MDM2 promoter) or pGL2-
hmdm-Px (DRE1 MDM2 promoter) luciferase-express-
ing plasmids given by Oren (Zauberman et al., 1995),
and a b-galactosidase construct. Luciferase activity was
quantified using a Luciferase Assay System (E1500)
from Promega (Madison, WI, USA) according to the
manufacturer’s instructions. Luciferase values were
normalized using b-galactosidase activity measured
using the Luminescent b-Galactosidase Detection Kit
II (631712) from Clontech/Takara (Kusatsu, Japan).
Luminescence levels are expressed as fold induction
versus the nontargeting siRNA-transfected controls.
2.7. p53 competition experiments
For p53 competition, cells were treated with bleomycin
for 3 h, lysed in oligo pulldown lysis buffer as
described in Section 2.4, and extracts were incubated
overnight with either pGL2-hmdm-Hx plasmid (Sec-
tion 2.6) or with minimum promoter-containing pGL2
basic. Lysates were immunoprecipitated as indicated
earlier in Section 2.4.
2.8. Lentivirus production and shRNA gene
interference
For effective gene interference, lentiviral vectors were
produced in HEK293T. Cells were transfected with
7 lg pMD2.G, 7 lg psPAX2 (VSV-G), and 7 lg of
either empty pLKO.1 puro or pLKO.1-shHERC2
(SHCLNG-NM_004667; Sigma-Aldrich/Merck) using
the calcium phosphate method as described elsewhere
(Cubillos-Rojas et al., 2014). Media were changed the
day after. Twenty-four hours later, media (which con-
tained the lentiviral particles produced) were collected,
filtered using Millex-HV 0.45 lm PVDF filters
(SLHV033RB; Millipore, Burlington, MA, USA), and
stored at 4 °C. Fresh media was added to the cells. The
same procedure was performed the day after. Both
media collections containing lentiviral vectors were
merged and stored in aliquots at 80 °C. Host A549
and H1299 cells were seeded at a confluence of 40–50%
in 6-well plates. The day after, 300 µL lentivirus-con-
taining media were added to each well and made up to
a total volume of 1 mL/well with fresh medium supple-
mented with polybrene (H9268; Sigma-Aldrich/Merck)
at a final concentration of 5 µgmL1. Media were
changed the day after. After 24 h, puromycin was
added at a final concentration of 1.5 µgmL1 for A549
and 3 µgmL1 for H1299 and left for at least 72 h
before experiments were performed. Noninfected cells
were used as a selection control. Cells were routinely
maintained in puromycin-containing media, which was
removed prior to each experiment.
2.9. Cell growth and clonogenic assays
For viability assays, the indicated cell lines were seeded
to a final concentration of 2 9 104 cells/well in three
wells of a 24-well plate per condition and time point.
Every 24 h, 1/10 volumes of MTT (M5655; Sigma/
Merck) (5 mgmL1 in PBS) was added per well to the
media in one of the plates and incubated for 1 h at
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37 °C in the cell incubator. Media were then dis-
carded, and formazan crystals were recovered with
DMSO and absorbance at k = 570 nm was determined
using a 96-well plate spectrophotometer. The results
are reported as percentage versus the 24-h time point.
For cell growth assays with crystal violet staining,
the indicated cell lines were seeded to a final concentra-
tion of 2 9 104 cells/well in three wells of a 24-well
plate per condition and time point. Every 24 h, the
media in one of the plates were discarded, cells were
washed with 1X PBS with mild rocking for 5 min at
room temperature and incubated with 0.2% crystal vio-
let (C0775; Sigma-Aldrich/Merck) dissolved in 0.5%
glutaraldehyde in water for 15 min with mild rocking
at room temperature. The excess dye was washed with
running tap water and allowed to dry overnight at
room temperature upside down. Dye that had adhered
to the cells was recovered with 10% acetic acid and
absorbance at k = 595 nm was determined using a 96-
well plate spectrophotometer. The results are reported
as percentage versus the 24-h time point.
Clonogenic assays were performed by seeding 2000
cells/well in 6-well plates and dying them with crystal
violet solution, as described above, 12 days after. The
results are reported as a percentage versus cells infected
with the lentivirus carrying the empty pLKO vector.
2.10. Cisplatin dose–response assays
The indicated cell lines were seeded at a final concen-
tration of 2 9 104 cells/well in a 24-well plate and left
overnight. A day later, the media were discarded and
replaced with fresh media containing the indicated
concentrations of cisplatin (CDDP) (P4394; Sigma-
Aldrich/Merck). After 48 h, cells were dyed with MTT
as described in Section 2.9.
2.11. Statistical analysis
The results shown are the means of, at least, three
independent experiments  SEM. Significance was cal-
culated by Student’s t-test using PRISM 5.00 software
from GraphPad (San Diego, CA, USA) and is indi-
cated as follows: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
3. Results
3.1. MDM2 binds HERC2 through oligomerized
p53
As it has been reported that HERC2 binds p53 (Cubil-
los-Rojas et al., 2014, 2017), and given that MDM2 is
a well-known interactor with p53 (Moll and Petrenko,
2004; Wu et al., 1993), we decided to investigate
whether these two events occur simultaneously. A
simultaneous interaction of HERC2 with both endoge-
nous p53 and MDM2 can be observed in immunopre-
cipitation experiments using specific anti-HERC2
(bvg3) antibody in U2OS cells (Fig. 1A). The interac-
tion of HERC2 with MDM2 is scarce, probably due to
the low levels of MDM2, which makes it difficult to
detect in protein complexes. It is well known that the
inhibition of proteasome activity increases MDM2 and
p53 levels. Thus, we decided to analyze this interaction
upon proteasome inhibition by previous treatment with
MG132 for 6 h. Under these conditions, MDM2 levels
increased and a strong interaction was detected
(Fig. 1A). This finding was also observed in other cell
lines such as HEK293T and A549 upon proteasome
inhibition as well (Fig. 1B). One of the defining protein
domains of HERC2 is CPH, which is also present in
Cul7 and PARC and is known to bind to p53
(Andrews et al., 2006; Cubillos-Rojas et al., 2014; Kas-
per et al., 2006; Kaustov et al., 2007; Nikolaev et al.,
2003). In the presence of MG132, we observed binding
of p53 as well as MDM2 to the Myc-tagged, CPH
domain-containing F3 region (residues 2292–2923) of
HERC2 (Fig. 1C). Reciprocally, HERC2 and p53 also
co-immunoprecipitated with Flag-MDM2 in trans-
fected HEK293T cells (Fig. 1D). In order to assess
whether the interaction between MDM2 and HERC2
was p53-dependent, we performed the same immuno-
precipitation approach in p53-null H1299 cells. After
pretreating cells with MG132, MDM2 does not bind
HERC2 in the absence of p53, as shown in Fig. 2A.
We wanted to know whether the oligomerization of
p53 was necessary for MDM2 binding to the HERC2-
p53 complex. We therefore transfected H1299 cells with
either wild-type (wt) p53 or with the R337C and L334P
p53 mutant variants found in Li-Fraumeni syndrome,
which are unable to oligomerize (Davison et al., 1998;
Itahana et al., 2009; Lomax et al., 1998). Only in the
wt p53-transfected H1299, it was possible to coim-
munoprecipitate p53 and MDM2 with HERC2
(Fig. 2B). Moreover, we tested p53 mutants for nuclear
localization signal (NLS) and for nuclear export
sequence (NES) since the latter is also known to be
defective in oligomerization (Itahana et al., 2009).
Immunoprecipitation of endogenous HERC2 yielded
evidence for MDM2 binding to p53 along with HERC2
only in H1299 cells expressing the wt- or NLS-p53. In
contrast, immunoprecipitation of HERC2 in the pres-
ence of the NES mutant failed to retrieve either p53 or
MDM2 (Fig. 2C). Altogether, these results show that
MDM2 binds HERC2 through oligomerized p53.
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3.2. HERC2 regulates MDM2 expression through
a p53-dependent transcriptional mechanism
Due to their ubiquitin ligase activity, binding of
HERC2 to MDM2 could suggest a possible mecha-
nism of ubiquitylation and subsequent proteasome-de-
pendent degradation of one of these two proteins. To
figure that out, we knocked HERC2 down by trans-
fecting U2OS cells with specific siRNA. HERC2
knockdown yielded a reduction in MDM2 protein
levels (Fig. 3A) compared to those in nontargeting
siRNA-transfected cells. To fully rule out similar recip-
rocal activity, we performed knockdown of MDM2 by
siRNA transfection and evaluated HERC2 expression
also in U2OS cells. In this case, HERC2 protein levels
were not affected by MDM2 downregulation
(Fig. 3B). We then decided to investigate the mecha-
nism by which MDM2 levels diminish upon HERC2
knockdown. We performed a time-course experiment
in the presence of protein translation inhibitor cyclo-
heximide (Kao et al., 2015; Wettstein et al., 1964) after
transfecting either HERC2-directed or nontargeting
siRNAs in U2OS cells. As indicated in Fig. 3C, no sig-
nificant differences in protein stability patterns were
observed following HERC2 knockdown. However,
MDM2 mRNA levels were effectively reduced upon
HERC2 depletion compared to the nontargeting con-
trol siRNA transfection (Fig. 3D). These data indicate
that the decline observed in MDM2 protein levels
upon HERC2 knockdown relies on a reduction in its
transcription rates rather than on a mechanism affect-
ing protein stability.
The MDM2 gene is under the control of a pro-
moter-containing two p53 response elements (RE1 and
RE2) (Wu et al., 1993). To confirm the involvement of
HERC2 in MDM2 transcriptional regulation through
p53, plasmids containing luciferase gene under the
control of either wt (pGL2-hmdm-Hx) or p53 response
element 1-lacking (DRE1) (pGL2-hmdm-Px) MDM2
promoter (Fig. 4A) were transfected into U2OS cells.
HERC2 knockdown significantly reduces luciferase
activity in cells transfected with the wt promoter-carry-
ing plasmid but not with the DRE1 promoter
(Fig. 4B). In addition to this, HERC2 knockdown did
not affect luciferase activity on the wt promoter in
p53-null H1299 cells (Fig. 4C). Together, these results
suggest that HERC2 controls MDM2 levels through a
p53-dependent transcriptional mechanism.
Fig. 1. HERC2 binds MDM2 and p53. (A) U2OS cells were either untreated () or treated (+) with proteasome inhibitor MG132 for 6 h and
protein extracts were immunoprecipitated (IP) against HERC2 using bvg3 antibody or incubated with pre-immune serum (PI) as a negative
control. Immunoprecipitation products were immunoblotted against the indicated proteins. (B) HEK293T and A549 cells were treated with
MG132, and immunoprecipitation was carried out as in (A). (C) HEK293T cells were transfected with Myc-tagged, CPH-containing HERC2
F3 region for 24 h, and immunoprecipitation against Myc epitope was performed as described for (A) after 6 h of MG132 pretreatment. (D)
HEK293T cells were transfected (+) with Flag-MDM2 or empty pcDNA3-Flag plasmid as a control for 24 h. Protein extracts were
immunoprecipitated against Flag epitope. Immunoprecipitation products were processed as described in (A). Shown data are representative
of, at least, three independent experiments.
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3.3. Binding of p53, but not HERC2 nor MDM2,
to MDM2 promoter
Since MDM2 expression is activated by p53, espe-
cially under DNA-damaging stress conditions (Toledo
and Wahl, 2006), we wondered whether the HERC2-
p53-MDM2 complex described above is present in
the MDM2 promoter region. To this end, we per-
formed oligo pulldown experiments in U2OS cells
with either p53 RE1-wt (wt) or p53 RE1-mutant
(mut) MDM2 promoter biotinylated oligonucleotides.
The p53 responsive element (RE) from the p21 pro-
moter was used as a positive control due to its affin-
ity for p53 and murine Col1a1 promoter Sp1
sequence was used as a negative control. Cells were
either treated with bleomycin, a DNA-damaging
agent known to promote p53 activation (Cubillos-
Rojas et al., 2014; Panchanathan et al., 2015 and
Fig. S1), or untreated as a control. As expected, the
results show that p53 binds to p21 promoter, with
an increase of phosphorylated and acetylated form
upon bleomycin treatment (Fig. 5A). Binding of p53,
both total and activated, to the wt MDM2 promoter
was similar. However, this binding was drastically
lower with the mut MDM2 promoter. No HERC2
nor MDM2 binding was detectable in either condi-
tions. NEURL4, a regulator of p53 transcriptional
activity through interaction with HERC2 and p53
(Cubillos-Rojas et al., 2017), was also analyzed and
similar results were obtained. These data show that
HERC2, NEURL4, and MDM2 do not bind the
promoter regions where p53 is bound. Since p53
transcriptional activity requires its tetramerization
(Itahana et al., 2009), we wanted to assess the
oligomerization state of p53 on the MDM2 pro-
moter. To this end, we carried out oligo pulldown
experiments in bleomycin-treated or bleomycin-un-
treated U2OS cells. Protein samples were then pro-
cessed either in the presence or in the absence of
0.04% glutaraldehyde solution as a crosslinker to
visualize oligomerization. We observed a high relative
amount of monomeric and dimeric p53 in total pro-
tein extracts (Input) whereas tetrameric p53 was
undetectable (Fig. 5B, left panel). The dimeric/mono-
meric ratio notably rose upon bleomycin treatment.
This increase was reduced by HERC2 interference
through siRNA transfection (Fig. 5B, left panel).
The tetrameric form was enriched in the protein
extracts bound to the biotinylated p53 RE1 from the
MDM2 wt promoter (oligo pulldown). HERC2
Fig. 2. Oligomerized p53 is required for the binding of MDM2 to HERC2. (A) p53-null H1299 cells were treated with MG132 for 6 h, and
protein extracts were immunoprecipitated (IP) against HERC2 with bvg3 antibody or incubated with pre-immune serum (PI) as a negative
control. Immunoprecipitation products were immunoblotted against the indicated proteins. (B, C) H1299 cells were transfected with the
indicated p53 constructs (for more details about constructs, see Itahana et al., 2009) for 24 h. Cells were treated for the last 6 h with
MG132, and immunoprecipitation was carried out as described in (A). Shown data are representative of, at least, three independent
experiments.
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silencing led to a lower amount of tetrameric p53
bound to the MDM2 promoter both in basal and in
bleomycin-treated conditions (Fig. 5B, right panel).
These findings show the absence of HERC2, MDM2,
or NEURL4 proteins on the MDM2 promoter, the
specific binding of p53 to MDM2 promoter and the
increase of oligomerized/activated p53 bound to this
promoter after DNA damage caused by bleomycin.
Fig. 3. HERC2 regulates MDM2 expression. (A) Nontargeting (NT) or HERC2-directed siRNAs were transfected (+) into U2OS for 72 h.
Protein extracts were immunoblotted against the indicated proteins. a-Tubulin was used as a loading control. The chart indicates band
quantification of three independent experiments. (B) Nontargeting (NT) or MDM2-directed siRNAs were transfected (+) into U2OS for 72 h.
Protein extracts were immunoblotted against the indicated proteins. a-Tubulin was used as a loading control. The chart indicates band
quantification of three independent experiments. (C) Nontargeting (NT) or HERC2-directed siRNAs were transfected into U2OS for 72 h.
Cells were treated, during the last 90 min, with 20 µM of the protein-synthesis inhibitor cycloheximide (CHX) for the indicated times. Protein
extracts were immunoblotted against the indicated proteins. a-Tubulin was used as a loading control. The chart indicates band
quantification. (D) Nontargeting (NT) or HERC2-targeted siRNAs were transfected into U2OS for 72 h. qRT–PCR experiments were
performed with total cDNA using specific Taqman probes against MDM2 and GAPDH as a loading control. Parallel protein extracts were
immunoblotted against the indicated proteins. a-Tubulin was used as a loading control. Data were analyzed by Student’s t-test. Error bars
indicate SEM from three independent experiments.
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3.4. Regulation of HERC2-p53-MDM2 complex
formation
During activation of p53-regulated gene transcription
such as that of p21 or MDM2 genes, MDM2 and p53
proteins should be released from the HERC2-p53-
MDM2 complex according to the results described
above. As shown earlier, p53 bound to the promoters
of these genes upon activation/DNA damage is prefer-
entially oligomerized, acetylated and phosphorylated.
To analyze this further, we performed immunoprecipi-
tation of HERC2 in U2OS cells both in basal and in
bleomycin-treated conditions. To detect MDM2, cells
were transfected with Flag-MDM2 construct. Since
antibodies against phosphorylated p53, acetylated p53,
and the antibody against HERC2 used to immunopre-
cipitate (bvg3) were produced in rabbits, cells were
also transfected with p53-CFP construct to avoid
interference of the antibodies against active p53 with
the immunoglobulins from rabbit sera (immunoglobu-
lin heavy-chain molar mass is about 50 kDa). Bleomy-
cin treatment induced both phosphorylation and
acetylation of p53 (Fig. 6A, Input). We observed that
MDM2 binding to the HERC2-p53 complex was
greatly reduced after bleomycin treatment whereas p53
binding was not notably affected. In these conditions,
phosphorylated and acetylated p53 remains bound to
HERC2. NEURL4 is also present in the complex
(Fig. 6A). Since there were no significant differences in
binding between HERC2 and p53 after bleomycin
treatment, these results suggest that only a small frac-
tion of p53 is bound to promoters under these condi-
tions. We hypothesized that promoters containing p53
response elements compete with HERC2 for the bind-
ing of p53. To test this hypothesis, we performed a
competition experiment in which plasmids containing
the wt MDM2 promoter (pGL2-hmdm-Hx) (Fig. 4A)
were incubated with bleomycin-treated U2OS cell
lysates overnight prior to immunoprecipitation. The
same luciferase-expressing plasmid backbone with min-
imum promoter (no MDM2 promoter sequences)
pGL2 basic was used as a negative control. Pre-incu-
bation of the pGL2-hmdm-Hx with the protein
extracts effectively abolished p53 binding to HERC2
in a dose-dependent manner. These data suggest that
p53 detaches from HERC2 and binds target gene pro-
moter (Fig. 6B).
3.5. Stable HERC2 interference enhances cell
growth and desensitizes cells against cisplatin in
the presence of wt p53
As argued above and in other articles (Cubillos-Rojas
et al., 2014), HERC2 is crucial for correct p53
Fig. 4. HERC2 knockdown reduces MDM2 promoter activation in a wt p53 context. (A) Schematic diagram of the MDM2 promoter region
in pGL2-hmdm-Hx (wt MDM2 promoter) and pGL2-hmdm-Px (p53DRE1 MDM2 promoter) plasmids (for more details see Zauberman et al.,
1995). (B, C) U2OS or p53-null H1299 cells were transfected with either nontargeting (NT) or HERC2-directed siRNAs for 72 h. During the
last 24 h, cells were transfected with luciferase-expressing vectors under the control of either wt MDM2 promoter or p53DRE1 MDM2
promoter where indicated and luciferase activity was measured. The charts represent normalized luciferase measurements versus the NT
series. Data were analyzed by Student’s t-test. Error bars indicate SEM from three independent experiments.
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transcriptional activity. Hence, we decided to investi-
gate whether stable HERC2 silencing would result in
the impairment of p53 physiological functions such as
cell proliferation regulation or cell death triggered by
DNA damage. Non-small-cell lung cancer (NSCLC)
A549 (wt p53) and H1299 (p53-null) cell lines were
infected with lentivirus carrying either an empty vector
(pLKO) or shRNA against HERC2 (shHERC2). To
further investigate the effects on p53 functionalities,
we took advantage of cis-diamminedichloro platinum
(II) (CDDP), also known as cisplatin, which is a
widely used chemotherapeutic drug that induces DNA
damage and apoptotic cell death in wt p53 contexts
(Fennell et al., 2016; Garcıa-Cano et al., 2015; Maccio
and Madeddu, 2013). HERC2 expression was assessed
by western blot following selection (Fig. 7A). In A549
shHERC2 cells, MDM2 and p21 levels are drastically
reduced. This decrease is partially recovered upon cis-
platin treatment. None of this is evident in p53-null
H1299 cells. HERC2 silencing stimulated cell growth
in A549 cells but had no significant effect in H1299 as
measured by MTT (Fig. 7B). Similar results were
obtained by crystal violet method (Fig. S2). Clono-
genic assays also performed by crystal violet suggest
that these phenotypes are maintained in long-term col-
ony formation cultures (Fig. S3). HERC2-silenced
A549 cells showed higher resistance against cisplatin
treatment than their control counterparts. However,
sensitivity toward cisplatin remained unchanged in
H1299 when interfering HERC2 versus no interference
by MTT (Fig. 7C) with similar tendencies by crystal
violet method (Fig. S4), thus confirming that HERC2
is necessary for the effect that p53 exerts on prolifera-
tion and cytotoxic response to chemotherapeutic
drugs. To further demonstrate that these effects rely
on the presence of HERC2 and p53 rather than in any
other differences among cell lines, we carried out phe-
notype rescue experiments in which A549 cells (both
pLKO and shHERC2) were transfected with the CPH-
containing F3 fragment of HERC2 (residues 2292–
Fig. 5. p53, but not HERC2 nor MDM2, binds biotinylated oligonucleotides from promoter regions. (A) U2OS cells were treated with
bleomycin for 3 h (+) or untreated () as a control, and oligo pulldown experiments were performed with protein extracts. Pulldown
products were immunoblotted against the indicated proteins. Shown data are representative of three independent experiments. The
membrane from the 55-kDa band was stained with Ponceau S solution (B) U2OS cells were transfected with either nontargeting (NT) or
HERC2-directed siRNAs for 72 h. During the last 3 h, cells were either treated with bleomycin (+) or untreated as a control () and oligo
pulldown experiments were performed as in (A). Pulldown products were split into two aliquots. One of them was incubated with 0.04%
glutaraldehyde before adding loading buffer and the other one remained untreated as a control. Pulldown products in both cases were
immunoblotted against p53. Shown data are representative of two independent experiments.
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2923) used in Fig. 1C. CPH domain ectopic expression
modestly reduces cell growth in HERC2-intact A549
pLKO cells. However, this parameter is drastically
diminished from HERC2-lacking cells upon CPH
transfection (Fig. 7D). Regarding response of A549
cells to cisplatin, CPH domain introduction could also
rescue HERC2 knockdown cells. As it is evident in
Fig. 7E, CPH transfection, which mildly sensitizes
A549 pLKO cells, strongly reverts shHERC2 protec-
tion against cisplatin resembling once more the nonsi-
lenced phenotype. These data confirm that HERC2
is necessary for complete functionalities of p53 in
cell contexts such as cell growth and response to
DNA-damaging drug treatment. (Raw data from this
set of experiments are available in Fig. S5).
4. Discussion
The ubiquitin ligase HERC2 forms a complex with
the NEURL4 protein that stabilizes NEURL4 (Al-
Hakim et al., 2012; Cubillos-Rojas et al., 2017; Galli-
gan et al., 2015). This complex interacts with the p53
tumor suppressor protein and regulates its transcrip-
tional activity by regulating its oligomerization
(Cubillos-Rojas et al., 2014, 2017). In the process of
activating the transcription of genes regulated by
p53, oligomerization of p53 precedes its acetylation
(Itahana et al., 2009), the acetylation being indispens-
able for its transcriptional activity (Tang et al.,
2008). In this model, HERC2 and NEURL4 function
as essential factors for the oligomerization of p53. In
nonstressed cells, p53 is normally kept under control
by the ubiquitin ligase MDM2. p53 and MDM2
form a negative feedback loop in which p53 activates
the transcription of MDM2, and MDM2 ubiquity-
lates p53 which inhibits its transcriptional activity,
facilitates its cytoplasmatic localization, and promotes
its degradation (Karni-Schmidt et al., 2016; Man-
fredi, 2010). Here, we demonstrate that under non-
stress conditions, the ubiquitin ligase MDM2 is part
of the complex formed by HERC2, NEURL4, and
p53. The interaction of MDM2 with this complex is
mediated by p53 since the interaction was not
observed in p53-null H1299 cells and transfection of
wt p53 in these cells recovered the interaction. The
transfection of mutant forms of p53 that cannot
form tetramers demonstrated that p53 must be in a
tetrameric form for MDM2 to interact and be part
of the complex with HERC2 and NEURL4. Previous
reports showing that the p53 tetramerization domain
is required for efficient ubiquitylation by MDM2
(Maki, 1999) and that p53 tetramers can be ubiquity-
lated (Brooks et al., 2007), are consistent with these
observations. Under stress conditions caused by bleo-
mycin-induced DNA damage, p53 is phosphorylated
and acetylated, remaining bound to the complex
while MDM2 is dissociated. These data are consis-
tent with previous studies showing that kinases acti-
vated by DNA damage such as ATM or ATR
phosphorylate MDM2 and p53, inhibiting MDM2
ability to polyubiquitylate p53 (reviewed by Cheng
and Chen, 2010). Furthermore, DNA damage kinases
induce MDM2 self-degradation (Stommel and Wahl,
2004). Since ATM, ATR, and DNA-PK interact with
HERC2 (Bekker-Jensen et al., 2010), it is possible
that the binding of these kinases to the HERC2-p53-
Fig. 6. Regulation of HERC2-p53-MDM2 complex formation. (A)
U2OS cells were transfected with Flag-MDM2 and p53-CFP for
24 h. During the last 3 h, cells were either treated with bleomycin
(+Bleo) or remained untreated as a control (Bleo) and protein
extracts were immunoprecipitated (IP) with either bvg3 antibody
against HERC2 or with pre-immune serum (PI) as a negative
control. Immunoprecipitation products were immunoblotted against
the indicated proteins. (B) U2OS cells were treated with bleomycin
for 3 h. Protein extracts were incubated overnight (+) with the
indicated amounts of either MDM2 promoter-containing luciferase-
expressing plasmid (pGL2-hmdm-Hx) or with minimum promoter-
containing luciferase-expressing plasmid (pGL2 basic) as a control
and immunoprecipitated as in (A). Shown data are representative
of, at least, two independent experiments.
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MDM2 complex is necessary to phosphorylate
MDM2 and p53. The phosphorylation of the car-
boxyl end of HERC2 by these kinases (Bekker-Jensen
et al., 2010) could also be involved in the MDM2
release mechanism of the HERC2-p53-MDM2 com-
plex after DNA damage. On the other hand, p53
acetylation does not occur on p53 mutants that are
incapable of forming tetramers because acetyltrans-
ferases cannot interact with them (Itahana et al.,
2009). Finally, consistent with previous reports
(Cubillos-Rojas et al., 2014; Kawaguchi et al., 2006;
Stommel et al., 1999; Weinberg et al., 2004), p53
exists largely in the dimeric form in nonstressed
U2OS cells. Upon stress signaling caused by DNA
damage by bleomycin, a fraction of p53 shifts to the
tetramer form in a phosphorylated and acetylated
state and binds more efficiently to DNA and acti-
vates p53 target genes such as p21 or MDM2.
Fig. 7. Stable HERC2 ablation confers a higher growth rate and reduced DNA damage sensitivity in wt p53 contexts. (A) p53-wt A549 and
p53-null H1299 cells were infected with lentivirus carrying either HERC2-directed shRNA (shHERC2) or empty pLKO vector (pLKO) as
control. After selection with puromycin, cells were treated with 3 µM cisplatin (CDDP) for 48 h. Protein extracts were immunoblotted
against the indicated proteins. Clathrin heavy chain (CHC) was used as loading control. (B) HERC2-knockdown and control pLKO A549 and
H1299 cells were seeded and checked for viability using the MTT method. The chart indicates viability rates compared to the 24-h point. (C)
Cells were seeded as in (B). 24 h after seeding, cells were treated with the indicated concentrations of cisplatin for 48 h and viability was
assessed using the MTT method. The charts indicate survival rates compared to those of untreated cells. (D) A549 pLKO and shHERC2
were transfected with the F3 fragment of HERC2 (residues 2292–2923 containing the CPH domain), and viability was measured 72 h after
transfection by MTT method. (E) A549 cells were transfected as in (D). Twenty-four hours after transfection, cells were treated with 1.5 µM
CDDP and incubated for additional 48 h prior MTT staining. Results are the mean of two independent experiments. Data were analyzed by
Student’s t-test. Error bars indicate SEM from three independent experiments.
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Together, our findings reveal the importance of
HERC2 in regulating the p53-MDM2 loop and sug-
gest a model (Fig. 8) whereby HERC2 functions at
least at three levels. First, HERC2 together with
NEURL4 is necessary for p53 to tetramerize, forming
a HERC2-NEURL4-p53 complex. At this stage,
HERC2 would function as a stimulator of oligomer-
ization through its CPH domain. Second, the existence
of the HERC2-NEURL4-p53 complex allows the
interaction of MDM2 with tetramerized p53, which
enables MDM2-dependent p53 ubiquitylation that
results in proteasomal degradation. In response to
DNA damage, this complex would also allow MDM2,
p53, and HERC2 phosphorylation, MDM2 release,
and p53 acetylation. At this stage, HERC2 would
function as a scaffolding factor that allows the recruit-
ment of all these proteins, a previously suggested func-
tion for the interaction between HERC2 and
NEURL4 (Galligan et al., 2015). Third, the location in
the nucleus of the HERC2-p53 complex (Cubillos-
Rojas et al., 2014) allows acetylated, phosphorylated,
and tetramerized p53 to interact with the p53-binding
sequences in the promoters of its target genes such as
p21 or MDM2. This interaction releases p53 from the
complex with HERC2 and activates the transcription
of the target genes that, in the case of MDM2, pro-
duces a negative feedback loop regulation of p53. At
this stage, HERC2 would participate in the transcrip-
tion activation process to facilitate the binding of p53
to its promoters.
Ubiquitin E3 ligases can be classified according to
their ligase domains into three main types: RING,
RING-between-RING (RBR), and HECT (Buetow
and Huang, 2016). HERC2 belongs to the HECT fam-
ily and MDM2 is a member of the RING family.
Here, we show that the ubiquitin ligases HERC2 and
MDM2 form a complex with p53. HERC2 functions
as a positive modulator stimulating p53 oligomeriza-
tion whereas MDM2 functions as a negative modula-
tor regulating p53 ubiquitylation. p53 can be a
substrate of several ubiquitin E3 ligases, but it seems
that MDM2 is the main ubiquitin E3 ligase for p53
(Haupt et al., 1997; Kubbutat et al., 1997; Michael
and Oren, 2003). MDM2 ubiquitylates p53 thus
Fig. 8. Working model of the role of HERC2 in p53-MDM2 loop regulation. The HERC2-NEURL4 complex binds oligomerized p53 through
the CPH domain of HERC2. The p53-HERC2-NEURL4 complex binds MDM2 and, in the basal state, MDM2 polyubiquitylates p53, thus
marking it for proteasomal degradation. Upon DNA damage (such as bleomycin treatment), DNA damage-sensing kinases phosphorylate
MDM2 and HERC2 thus detaching MDM2 from the complex. Phosphorylated MDM2 is unstable, is autopolyubiquitylated, and later is
degraded by proteasome as well. This situation also induces activation of p53, in terms of phosphorylation and acetylation, and, later, its
translocation to the promoters of its targeted genes such as p21 or MDM2 itself the protein product of which can bind p53 and begin the
regulatory loop again.
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labeling it for nuclear-cytoplasmatic shuttle
(monoubiquitylation) or for proteasome-dependent
degradation (polyubiquitylation) (Li, 2003).
Autopolyubiquitylation and later proteasome-depen-
dent degradation have been described as the main
pathway of MDM2 degradation (Fang et al., 2000;
Honda and Yasuda, 2000). Because MDM2 knock-
down does not regulate HERC2 levels, it is likely that
MDM2 does not ubiquitylate HERC2 for proteasome-
dependent degradation. HERC2 depletion experiments
show that p53 and MDM2 protein levels do not
increase, suggesting that HERC2 does not ubiquitylate
these proteins for proteasome-dependent degradation.
Genetic studies have confirmed the physiological
importance of these genes. Thus, while TP53 knockout
mice are viable despite being prone to developing
tumors (Donehower et al., 1992; Jacks et al., 1994),
MDM2 or HERC2 knockout mice are lethal during
embryonic phase (Cubillos-Rojas et al., 2016; Jones
et al., 1995; Montes de Oca Luna et al., 1995). TP53
knockout mice can rescue MDM2 knockout mice
(Jones et al., 1995; Montes de Oca Luna et al., 1995)
but they cannot rescue HERC2 knockout mice (Cubil-
los-Rojas et al., 2016). These results suggest that an
increment in p53 levels during the embryonic phase is
the cause for the unviability of MDM2 knockout ani-
mals. In the case of HERC2 knockout mice, these data
imply that HERC2 has an essential role during devel-
opment and that this function is independent of its
regulation of p53 activity. HERC2 ubiquitylation sub-
strates could be involved in the essential function of
HERC2 during development. In this sense, proteins
involved in DNA repair mechanisms (such as XPA,
Kang et al., 2010 and BRCA1, Wu et al., 2010) and in
iron homeostasis (such as FBXL5, Moroishi et al.,
2014) are targeted by HERC2 for proteasome-depen-
dent degradation. BRCA1 or FBXL5 deficiency results
in early embryonic lethality in the same way as
HERC2 deficiency (Gowen et al., 1996; Liu et al.,
1996; Moroishi et al., 2011). Although these HERC2
substrates are expected to be increased in HERC2
knockout mice, we cannot discard a lethality by a dys-
regulation of their cellular functions by overexpres-
sion.
p53 functions as a tumor suppressor that protects
cells from malignant transformation, and its inactiva-
tion is associated with tumorigenesis. The importance
of p53 in human cancer is evident given that the
TP53 gene is mutated in about half of all sporadic
cancers and in patients with Li-Fraumeni syndrome,
who are cancer prone (Li and Fraumeni, 1969) and
harbor germline mutations in the TP53 gene (Freed-
Pastor and Prives, 2012; Manfredi, 2010). Analysis of
p53 mutations in patients with Li-Fraumeni syndrome
revealed that the mutation frequency relative to the
length of the DNA binding domain and in the
oligomerization domain is almost the same (Kamada
et al., 2011, 2016). Because mutations in Li-Fraumeni
syndrome occur within the oligomerization domain
with considerable frequency, it has been proposed
that transcriptional defects and deregulated MDM2
circuitry are likely contributors to this pathology
(Katz et al., 2018). Our data suggest that HERC2
could also protect cells from malignant transforma-
tion. In this context, mutations in HERC2 have been
detected in T-cell prolymphocytic leukemia (Johans-
son et al., 2018) and in gastric and colorectal carcino-
mas with microsatellite instability (Yoo et al., 2011).
Moreover, the HERC2 locus has been associated with
cutaneous melanoma (Amos et al., 2011) and uveal
melanoma (Ferguson et al., 2016). In tumors with wt
p53, an attractive approach is to reactivate p53. Nut-
lin-3 can promote this reactivation by blocking the
MDM2-p53 interaction (Vassilev, 2004). Several Nut-
lin-3 analogs are in clinical trials for treatment of
human cancers (Burgess et al., 2016; Zhao et al.,
2015). Another way in which to reactivate p53 is by
stimulating its oligomerization. Drugs causing
nongenotoxic activation of p53 oligomerization may
be potential candidates for cancer therapy. In this
context, induction of HERC2 activity leading to
higher p53 oligomerization may be a potential target
for cancer therapy.
5. Conclusions
MDM2 ubiquitin E3 ligase forms a complex along
with HERC2 and NEURL4 necessarily through
oligomerized p53. HERC2 knockdown results in
reduced MDM2 promoter activation and, hence,
diminished MDM2 mRNA expression in wt p53 con-
texts. Upon bleomycin-induced DNA damage, first
MDM2 is released of the oligomeric p53/HERC2/
NEURL4 complex, and then, p53 response elements-
containing promoters compete with the HERC2-
NEURL4 tandem for active p53 binding. Functional
HERC2 is required for the maintenance of p53 activity
in terms of cell growth control and response to cis-
platin-induced cell death.
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